Global Neuroendocrine Tumors Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Neuroendocrine Tumors Market Size

• The global neuroendocrine tumors market size was valued at USD 3.56 billion in 2024 and is expected to reach USD 7.87 billion by 2032, at a CAGR of 10.4% during the forecast period
• The market growth is largely fueled by the increasing incidence and prevalence of neuroendocrine tumors, coupled with significant advancements in diagnostic techniques leading to earlier and more accurate detection
• Furthermore, rising research and development activities, particularly in targeted therapies and novel treatment modalities such as peptide receptor radionuclide therapy (PRRT) and immunotherapies, are expanding treatment options and driving the adoption of these solutions, thereby significantly boosting the industry's growth

Neuroendocrine Tumors Market Analysis

• Neuroendocrine tumors (NETs), a diverse group of cancers originating from neuroendocrine cells, are increasingly recognized as a critical area in oncology. Their varied presentation and often slow growth necessitate advanced diagnostic and treatment modalities across both functional and non-functional types
• The escalating demand for neuroendocrine tumor treatments is primarily fueled by the increasing incidence and prevalence of these tumors globally, significant advancements in diagnostic techniques leading to earlier and more accurate detection, and a rising focus on research and development for novel and targeted therapies
• North America dominates the neuroendocrine tumors market with the largest revenue share of 42.5% in 2024, characterized by a robust healthcare infrastructure, high healthcare expenditure, the presence of key pharmaceutical and biotechnology companies, and a higher awareness and diagnosis rate of NETs. The U.S. specifically drives substantial growth due to extensive research initiatives and patient access to cutting-edge therapies
• Asia-Pacific is expected to be the fastest growing region in the neuroendocrine tumors market during the forecast period due to improving healthcare infrastructure, increasing awareness about NETs, rising disposable incomes, and a growing patient population seeking advanced treatment options
• 非機能性NETセグメントは、無症状の性質により進行した段階での診断が遅れることや、高度な画像技術の普及による偶発的な検出の増加により、2024年には52.1％の市場シェアで神経内分泌腫瘍市場を支配します。

レポートの範囲と神経内分泌腫瘍市場のセグメンテーション    

神経内分泌腫瘍の市場動向

「標的治療と精密医療の進歩」

• 世界の神経内分泌腫瘍（NET）市場における重要かつ加速的なトレンドは、高度に標的化された治療法とプレシジョン・メディシン（精密医療）アプローチの継続的な開発と導入です。これは、個々の腫瘍の特定の分子特性を理解し、従来の化学療法を超えた治療法をカスタマイズすることを含みます。
  • 例えば、エベロリムスやスニチニブなどの標的薬は膵臓NETの治療薬として承認されており、無増悪生存期間の改善が実証されています。同様に、ルタセラなどのペプチド受容体放射性核種療法（PRRT）は、標的放射線を腫瘍細胞に直接照射することでソマトスタチン受容体陽性NETの治療に革命をもたらし、進行期症例においてより正確で効果的な治療法を提供しています。
• NETの複雑かつ多様な性質により、多職種連携によるチームアプローチと専門の神経内分泌腫瘍センターの設立が促進されています。これらのセンターは、内分泌科医、腫瘍医、外科医、放射線科医、病理医を結集し、包括的かつ個別化された患者ケアを提供することで、最適な治療戦略と転帰の改善につながります。この協調的なアプローチは、NETに伴う多様な臨床症状と治療経路を管理するために不可欠です。
• NET分野における研究開発投資は、既存の治療法を超えた新たな治療法の開拓に向けて、堅調な増加傾向にあります。これには、耐性克服と奏効率向上のための新たな標的療法、免疫療法、併用療法の研究が含まれます。新たな分子標的の特定と、NET細胞の増殖と増殖を特異的に阻害する薬剤の開発に重点が置かれており、患者にとってより効果的で持続的な治療選択肢を提供することを目指しています。
• よりインテリジェントで正確、かつ統合された診断と治療アプローチへのこの傾向は、神経内分泌腫瘍の管理の状況を根本的に変えるものである。

神経内分泌腫瘍市場の動向

ドライバ

「発生率の増加と診断および治療の進歩」

• 神経内分泌腫瘍（NET）の世界的な発生率と有病率の増加は、診断技術の大きな進歩と新しい治療オプションの継続的な開発と相まって、神経内分泌腫瘍市場の需要の高まりの主な要因となっています。
  • 例えば、NETの世界的な発生率は着実に増加しており、ガリウム68ドータテートPET/CTスキャンなどの診断方法の改善により、より早期かつ正確な検出が可能になっています。企業は研究開発に積極的に投資しており、新たな標的療法や放射性リガンド療法によって治療範囲が拡大し、患者の転帰が改善されています。
• 医療従事者がNETの特定能力を高め、研究によってより効果的で的を絞った治療法が生まれるにつれ、包括的な管理戦略への強い要請が高まっています。この傾向は、疾患の複雑さと多職種連携ケアのメリットに対する理解の深まりによってさらに後押しされています。
• さらに、NETに関する医療関係者と一般市民の意識の高まりにより、より多くの患者が迅速な診断と治療を求めるようになっています。個々の腫瘍の特性に合わせた個別化医療のアプローチの開発も、より効果的で毒性の少ない治療選択肢を提供することで市場を牽引しています。
• 革新的な治療法の臨床試験数の増加と、この治療分野における製薬企業およびバイオテクノロジー企業による投資の増加は、神経内分泌腫瘍市場の成長を促進する重要な要因です。NET患者のアンメットニーズへの対応と生活の質の向上に重点が置かれていることも、市場拡大に寄与しています。

抑制/挑戦

「診断と治療の高額な費用と診断の複雑さ」

• 神経内分泌腫瘍（NET）の診断と治療にかかる莫大な経済的負担をめぐる懸念は、市場への浸透と患者アクセス拡大の大きな課題となっています。高度な画像診断、専門的な病理学、そして革新的な治療法に伴う高額な費用は、多くの患者にとって負担が大きく、世界中の医療予算を圧迫する可能性があります。
  • 例えば、ペプチド受容体放射性核種療法などの治療法は、効果は高いものの、高額な費用がかかります。同様に、ガリウム68ドータテートPET/CTスキャンなどの高度な診断ツールは、正確な病期分類に不可欠であるものの、かなりの費用がかかります。こうした高額な費用は、特に償還制度が限られている医療制度や発展途上地域では、治療の遅延や服薬不遵守につながる可能性があります。
• 強力な償還枠組み、患者支援プログラム、および一部の治療に対するより費用対効果の高いジェネリックまたはバイオシミラーの選択肢の開発を通じてこれらの経済的障壁に対処することは、患者のアクセスを改善するために重要である。
• さらに、NETの診断には固有の複雑さが伴い、大きな障害となっています。NETは希少性、多様な臨床症状、そしてしばしば非特異的な症状を呈するため、診断までの期間が長引いたり、誤診につながる可能性があります。
• 普遍的に受け入れられ、容易にアクセスできる早期診断バイオマーカーの欠如が、この複雑さの一因となっています。この診断上の課題は適切な治療開始を遅らせ、疾患の進行や予後不良につながる可能性があります。

神経内分泌腫瘍市場の展望

市場は、分類、場所、グレード、タイプ、製品、エンドユーザー、流通チャネルに基づいてセグメント化されています。

• 分類別

神経内分泌腫瘍市場は、分類に基づき、機能性NETと非機能性NETに分類されます。非機能性NETセグメントは、無症状であるため診断が遅れ、より進行した段階での診断につながること、そして高度な画像技術の普及により偶発的な発見が増加していることから、2024年には52.1%の市場シェアを獲得し、市場をほぼ独占するでしょう。これらの腫瘍は、ホルモン分泌ではなく腫瘍の質量効果によって症状が現れるまで、しばしば検出されません。

非機能性NETセグメントも、診断画像の継続的な改善により、これまで発見されていなかった無症候性腫瘍の検出率が向上することから、最も急速に成長するセグメントになると予測されています。

• サイト別

神経内分泌腫瘍市場は、部位別に肺、膵臓、消化管（GI）、虫垂に分類されます。2024年には、消化管（GI）セグメントが最大の市場収益シェアを占めました。この優位性は、消化管NETが最も一般的なサブタイプであり、全NETの55～70%を占めていることに起因しています。そのため、消化管が主な発生部位として最も多く見られます。

消化管（GI）セグメントは、胃がんの罹患率の上昇と強力な製品パイプラインの存在を背景に、世界の神経内分泌腫瘍（NET）市場において、2025年から2032年にかけて最も高い年平均成長率（CAGR）を記録すると予想されています。このセグメントの成長は、診断技術の進歩と新たな治療選択肢の開発によってさらに支えられています。

• 学年別

神経内分泌腫瘍市場は、グレード1、グレード2、グレード3に分類されます。多くのNET診断がこの中増殖性カテゴリーに分類され、継続的なモニタリングと治療介入が必要となるため、グレード2セグメントは2024年に大きな市場シェアを占めると予想されます。

グレード 3 セグメントは、新規かつ高額な治療法を含む即時かつ集中的な全身治療レジメンを必要とするこれらの高グレード腫瘍の攻撃的な性質によって、最も高い成長率を示すことが予想され、これらのソリューションに対する需要が高まっています。

• タイプ別

神経内分泌腫瘍市場は、その種類に基づいて診断と治療に分類されます。治療セグメントは、NETと診断されると、薬物療法から外科的治療まで、様々な治療法を含む継続的かつ長期的な治療介入が必要となるため、2024年には最大の市場収益シェアを占めました。

診断分野は、画像技術の継続的な進歩と、NETのより早期かつ正確な検出を可能にする新しいバイオマーカーの発見に支えられ、最も速い成長率を示すことが予想され、治療経路に入る患者プールが増加します。

• 製品別

On the basis of product, the neuroendocrine tumors market is segmented into somatostatin analogs, targeted therapy, and chemotherapy. The somatostatin analogs segment dominates the neuroendocrine tumors market with the largest revenue share of 74% in 2024. This is driven by their established efficacy in both controlling symptoms and inhibiting tumor growth in a large proportion of somatostatin receptor-positive NETs, positioning them as a first-line and long-term treatment option

The targeted therapy segment is anticipated to witness the fastest CAGR during the forecast period, fueled by ongoing research and development efforts leading to the approval of new, highly specific drugs that offer improved efficacy and a more favorable side-effect profile for various NET subtypes

• By End User

On the basis of end user, the neuroendocrine tumors market is segmented into hospitals, specialty clinics, radiation centers, home healthcare, and others. The Hospitals segment held the largest market revenue share in 2024, driven by their comprehensive infrastructure, access to multidisciplinary teams, advanced diagnostic capabilities, and the capacity to administer complex, often inpatient, treatments such as PRRT and specialized surgeries.

The specialty clinics segment is anticipated to grow at the highest CAGR during the forecast period, which can be attributed to patients' increasing preference for outpatient care models and specialized expertise offered by these centers, leading to greater patient traffic

• By Distribution Channel

On the basis of end user, the neuroendocrine tumors market is segmented into Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other. The retail pharmacies segment accounted for the largest market revenue share in 2024, driven by their widespread accessibility, established consumer trust, and the ability to offer a broad range of products, from over-the-counter medications to prescription drugs. Retail pharmacies are often the first point of contact for individuals seeking medications, making them a crucial part of the healthcare system.

The direct tender segment is expected to witness the fastest compound annual growth rate (CAGR) from 2025 to 2032 in the global neuroendocrine tumors market, driven by the increasing focus on cost-effective procurement strategies by healthcare providers and the growing presence of suppliers in the market. This segment's growth is further supported by the expansion of healthcare infrastructure and the rising demand for specialized treatments for neuroendocrine tumors

Neuroendocrine Tumors Market Regional Analysis

• North America dominates the neuroendocrine tumors market with the largest revenue share of 42.5% in 2024, driven by characterized by a robust healthcare infrastructure, high healthcare expenditure, the presence of key pharmaceutical and biotechnology companies, and a higher awareness and diagnosis rate of NETs
• Consumers and healthcare providers in North America highly value access to advanced diagnostic techniques and cutting-edge targeted therapies, alongside robust reimbursement policies that facilitate the adoption of new treatments
• This widespread adoption is further supported by high healthcare expenditure, a technologically advanced medical infrastructure, and the growing preference for personalized medicine approaches, establishing North America as a key innovation hub for NET management

U.S. Neuroendocrine Tumors Market Insight

The U.S. neuroendocrine tumor market captured the largest revenue share of 74% within North America in 2024, fueled by the swift uptake of advanced diagnostic modalities and the expanding availability of novel therapeutic options. Healthcare providers are increasingly prioritizing the enhancement of NET management through precise diagnostic tools and effective treatment regimens. The growing preference for specialized care centers, combined with robust demand for targeted therapies and personalized medicine approaches, further propels the NET industry. Moreover, the increasing integration of clinical research and development, supported by strong governmental funding and pharmaceutical investments, is significantly contributing to the market's expansion

Europe Neuroendocrine Tumors Market Insight

The Europe neuroendocrine tumor market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing R&D spending, favorable health reimbursement policies, and strategic collaborations among key players. The increase in NET incidence, coupled with a growing focus on early diagnosis and multidisciplinary management, is fostering the adoption of advanced NET treatments. European healthcare systems are also drawn to the benefits of established treatment protocols and increasing awareness campaigns by patient advocacy groups. The region is experiencing significant growth across various treatment modalities, with new therapies being incorporated into clinical practice and national guidelines

U.K. Neuroendocrine Tumors Market Insight

The U.K. neuroendocrine tumor market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the escalating focus on improving cancer outcomes and a desire for heightened access to innovative therapies. In addition, concerns regarding the often late diagnosis of NETs are encouraging both healthcare providers and patients to seek advanced diagnostic and treatment solutions. The UK’s robust healthcare system, alongside its increasing investment in cancer research and clinical trials, is expected to continue to stimulate market growth

Germany Neuroendocrine Tumors Market Insight

The Germany neuroendocrine tumor market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of rare cancers and the demand for technologically advanced, high-quality healthcare solutions. Germany’s well-developed infrastructure, combined with its emphasis on innovation and robust reimbursement policies, promotes the adoption of advanced NET diagnostics and therapies, particularly in specialized oncology centers. The integration of precision medicine approaches and a strong preference for research-backed solutions align with local consumer and medical expectations, further driving market expansion

Asia-Pacific Neuroendocrine Tumors Market Insight

The Asia-Pacific neuroendocrine tumor market is poised to grow at the fastest CAGR during the forecast period, driven by increasing incidence of NETs, rising healthcare expenditure, and technological advancements in countries such as China, Japan, and India. The region's growing inclination towards improving cancer care, supported by government initiatives promoting healthcare infrastructure development, is driving the adoption of advanced NET treatments. Furthermore, as APAC witnesses a greater focus on early diagnosis and access to innovative therapies, the affordability and accessibility of NET management are expanding to a wider patient base

Japan Neuroendocrine Tumors Market Insight

The Japan neuroendocrine tumor market is gaining momentum due to the country’s advanced healthcare infrastructure, focus on precision medicine, and demand for high-quality specialized care. The Japanese market places a significant emphasis on diagnostic accuracy and treatment efficacy, and the adoption of advanced NET therapies is driven by the increasing number of diagnosed cases and clinical research. The integration of multidisciplinary care approaches with other advanced medical technologies, such as sophisticated imaging, is fueling growth. Moreover, Japan's aging population is such asly to spur demand for effective and comprehensive NET management solutions.

India Neuroendocrine Tumors Market Insight

The India neuroendocrine tumor market accounted for the largest market revenue share in Asia Pacific in 2024, attributed to the country's expanding middle class, rapid urbanization, and improving access to specialized medical facilities. India stands as a rapidly growing market for cancer care, and advanced NET diagnostics and treatments are becoming increasingly popular in major metropolitan areas. The push towards improving cancer screening programs and the increasing availability of specialized oncology services, alongside growing domestic pharmaceutical capabilities, are key factors propelling the market in India

Neuroendocrine Tumors Market Share

The neuroendocrine tumors industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Bristol-Myers Squibb (U.S.)
• Viatris Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Novartis AG (Switzerland)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Lilly (U.S.)
• Lupin (India)
• Exact Sciences Corporation (U.S.)
• Pfizer Inc. (U.S.)
• Ipsen Pharma (France)
• Advanced Accelerator Applications SA (France)
• BioSynthema Inc. (U.S.)
• Bionano Genomics, Inc. (U.S.)
• Illumina, Inc. (U.S.)
• GSK plc (U.K.)
• HUTCHMED (China)

Latest Developments in Global Neuroendocrine Tumors Market

• In April 2025, A new Phase 1 clinical trial has opened for enrollment at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, for patients with high-grade neuroendocrine tumors. This trial will test a novel combination of immunotherapy drugs (nivolumab and ipilimumab) paired with an oncolytic (tumor-busting) virus, SVV-001 (Seneca Valley Virus-001), injected directly into the tumors
• In February 2025, The U.S. Food and Drug Administration (FDA) approved mirdametinib (Gomekli) for the treatment of neurofibromatosis type 1 (NF1) in patients who have symptomatic plexiform neurofibromas not amenable to complete surgical resection. While not directly a neuroendocrine tumor, NF1 is a genetic disorder that can cause various tumors, including some with neuroendocrine features. This approval provides a significant non-surgical option for a challenging tumor type within a related patient population
• In April 2024, Novartis received U.S. Food and Drug Administration (FDA) approval for Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients. This approval marks a significant advancement, as Lutathera becomes the first radioligand therapy specifically approved for children with GEP-NETs, offering new hope for young patients and expanding the scope of precision medicine in pediatric oncology
• In March 2024, Crinetics Pharmaceuticals reported positive topline results from its Phase 2 open-label study of paltusotine, an investigational oral somatostatin receptor type 2 (SST2) nonpeptide agonist, in carcinoid syndrome. Paltusotine was shown to result in rapid and sustained reductions in the frequency and severity of flushing episodes and bowel movements associated with neuroendocrine tumors
• In December 2023, Bristol Myers Squibb (BMS) announced the acquisition of RayzeBio for approximately USD 4.1 billion. RayzeBio is a clinical-stage radiopharmaceutical company with a lead asset, RYZ101, targeting somatostatin receptor 2 (SSTR2), which is over-expressed in GEP-NETs and extensive stage small cell lung cancer (ES-SCLC). This acquisition significantly expands BMS's presence in the radiopharmaceutical therapeutics (RPTs) space and aims to strengthen its oncology pipeline

SKU-37175